GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Total Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Liabilities | ₹18,661 Cr | ₹14,925 Cr | ₹13,309 Cr | ₹17,566 Cr | ₹15,397 Cr |
What is the latest Total Liabilities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Total Liabilities |
|---|---|
| Mar2026 | ₹18,661 Cr |
| Mar2025 | ₹14,925 Cr |
| Mar2024 | ₹13,309 Cr |
| Mar2023 | ₹17,566 Cr |
| Mar2022 | ₹15,397 Cr |
How is Total Liabilities of GLENMARK PHARMACEUTICALS Trending?
| Years | Total Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹18,661 Cr | 25.03 | |
| Mar2025 | ₹14,925 Cr | 12.15 | |
| Mar2024 | ₹13,309 Cr | -24.23 | |
| Mar2023 | ₹17,566 Cr | 14.08 | |
| Mar2022 | ₹15,397 Cr | - | |
Compare Total Liabilities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹63,974.7 Cr | -0.9% | -6.2% | 16.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹424,466.0 Cr | -0.8% | -5.1% | 6.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹246,222.0 Cr | -3.2% | -1.4% | 53.7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹176,300.0 Cr | -1.6% | -6% | 32.1% | Stock Analytics | |
| CIPLA | ₹107,447.0 Cr | 0% | -3.6% | -13.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,471.0 Cr | 3.1% | 8.7% | -1.5% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | -0.9% |
-6.2% |
16.3% |
| SENSEX | -0.1% |
-2.3% |
-10.7% |
You may also like the below Video Courses